2023. Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s154. DOI:https://doi.org/10.25251/skin.7.supp.154.